IPH5201 and Durvalumab in Patients With Resectable Non-Small Cell Lung Cancer (MATISSE)
Status:
Recruiting
Trial end date:
2026-09-01
Target enrollment:
Participant gender:
Summary
The study is intended to assess the safety and efficacy of neoadjuvant combination of IPH5201
and durvalumab in addition to standard chemotherapy and adjuvant combination of IPH5201 and
durvalumab in untreated patients with resectable, early-stage (stage II to IIIA) non-small
cell lung cancer (NSCLC).